Participant Basic Agreement (PBA) Opportunity - Threat Agnostic Host-Directed Therapeutics
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Defense (DoD), through the Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), invites participation in the HEALER portfolio. This initiative seeks to develop threat-agnostic, host-directed therapeutics to enhance the body's resilience against CBRN threats, focusing on dual-use applications. This is a Special Notice for a Participant Basic Agreement (PBA) opportunity.
Purpose & Scope
The HEALER program aims to create a new generation of therapeutics that enable the 'Host' to recover from physiological impacts and maintain operational effectiveness. The focus is on delivering medical countermeasures that provide layered physiological protection by targeting critical host systems, including:
- Neurological Protection
- Respiratory Stabilization
- Immune Modulation
- Hematologic & Vascular Function
- Cellular Stress & Repair Pathways This integrated approach seeks to build a diverse and robust portfolio of threat-agnostic capabilities.
Call for Collaborators
CPE CBRND is seeking two types of collaborators:
- Therapeutic Development Collaborators: Developers of host-directed therapeutic candidates.
- Drug Development Support Collaborators: Organizations specializing in contract research, development, and manufacturing (CROs/CDMOs), preclinical testing, clinical trial execution, cGMP manufacturing, regulatory submissions, and advanced modeling.
Contract Details & Authority
This opportunity will be executed under a Participant Basic Agreement (PBA). Projects may be awarded under the authority of 10 U.S.C. §4021, §4022, and §4023, which are not subject to the provisions of the Competition in Contracting Act of 1984.
- Contract Type: Participant Basic Agreement (PBA)
- Set-Aside: None specified (open to all drug development organizations)
- Published Date: April 23, 2026
- Response Date: Not provided.
Submission Requirements
Interested entities must submit a white paper (not to exceed five pages, excluding cover page). Submissions should also state the entity's willingness to team or collaborate with other PBA holders.
- For Therapeutic Development Collaborators: White papers must cover product description, efficacy data, regulatory & clinical status, manufacturing capabilities, and company profile.
- For Drug Development Support Collaborators: White papers should summarize core capabilities, relevant experience (complex biologics/small molecules, FDA regulatory), available infrastructure, and technology.
Additional Notes
Prospective awardees MUST be registered in the System for Award Management (SAM) database.
- Points of Contact: Hunter Robinson (hunter.t.robinson4.civ@army.mil) and Alexander Mayatte (alexander.z.mayatte.civ@army.mil).